Rachel Loewy1, Melissa Fisher2, Danielle A Schlosser1, Bruno Biagianti3, Barbara Stuart1, Daniel H Mathalon2, Sophia Vinogradov4. 1. Department of Psychiatry, University of California, San Francisco, San Francisco, CA; 2. Department of Psychiatry, University of California, San Francisco, San Francisco, CA; Department of Psychiatry, San Francisco Department of Veterans Affairs Medical Center, San Francisco, CA. 3. Department of Psychiatry, San Francisco Department of Veterans Affairs Medical Center, San Francisco, CA. 4. Department of Psychiatry, University of California, San Francisco, San Francisco, CA; Department of Psychiatry, San Francisco Department of Veterans Affairs Medical Center, San Francisco, CA Sophia.vinogradov@ucsf.edu.
Abstract
OBJECTIVE: Individuals at clinical high risk (CHR) for psychosis demonstrate cognitive impairments that predict later psychotic transition and real-world functioning. Cognitive training has shown benefits in schizophrenia, but has not yet been adequately tested in the CHR population. METHODS: In this double-blind randomized controlled trial, CHR individuals (N = 83) were given laptop computers and trained at home on 40 hours of auditory processing-based exercises designed to target verbal learning and memory operations, or on computer games (CG). Participants were assessed with neurocognitive tests based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative (MATRICS) battery and rated on symptoms and functioning. Groups were compared before and after training using a mixed-effects model with restricted maximum likelihood estimation, given the high study attrition rate (42%). RESULTS: Participants in the targeted cognitive training group showed a significant improvement in Verbal Memory compared to CG participants (effect size = 0.61). Positive and Total symptoms improved in both groups over time. CONCLUSIONS: CHR individuals showed patterns of training-induced cognitive improvement in verbal memory consistent with prior observations in schizophrenia. This is a particularly vulnerable domain in individuals at-risk for psychosis that predicts later functioning and psychotic transition. Ongoing follow-up of this cohort will assess the durability of training effects in CHR individuals, as well as the potential impact on symptoms and functioning over time. Clinical Trials Number: NCT00655239. URL: https://clinicaltrials.gov/ct2/show/NCT00655239?term=vinogradov&rank=5. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2016.
RCT Entities:
OBJECTIVE: Individuals at clinical high risk (CHR) for psychosis demonstrate cognitive impairments that predict later psychotic transition and real-world functioning. Cognitive training has shown benefits in schizophrenia, but has not yet been adequately tested in the CHR population. METHODS: In this double-blind randomized controlled trial, CHR individuals (N = 83) were given laptop computers and trained at home on 40 hours of auditory processing-based exercises designed to target verbal learning and memory operations, or on computer games (CG). Participants were assessed with neurocognitive tests based on the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative (MATRICS) battery and rated on symptoms and functioning. Groups were compared before and after training using a mixed-effects model with restricted maximum likelihood estimation, given the high study attrition rate (42%). RESULTS:Participants in the targeted cognitive training group showed a significant improvement in Verbal Memory compared to CG participants (effect size = 0.61). Positive and Total symptoms improved in both groups over time. CONCLUSIONS: CHR individuals showed patterns of training-induced cognitive improvement in verbal memory consistent with prior observations in schizophrenia. This is a particularly vulnerable domain in individuals at-risk for psychosis that predicts later functioning and psychotic transition. Ongoing follow-up of this cohort will assess the durability of training effects in CHR individuals, as well as the potential impact on symptoms and functioning over time. Clinical Trials Number: NCT00655239. URL: https://clinicaltrials.gov/ct2/show/NCT00655239?term=vinogradov&rank=5. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2016.
Authors: A Bechdolf; M Wagner; S Ruhrmann; S Harrigan; V Putzfeld; R Pukrop; A Brockhaus-Dumke; J Berning; B Janssen; P Decker; R Bottlender; K Maurer; H-J Möller; W Gaebel; H Häfner; W Maier; J Klosterkötter Journal: Br J Psychiatry Date: 2011-11-10 Impact factor: 9.319
Authors: J D Ragland; R C Gur; J Raz; L Schroeder; C G Kohler; R J Smith; A Alavi; R E Gur Journal: Am J Psychiatry Date: 2001-07 Impact factor: 18.112
Authors: Paul Allen; Marc L Seal; Isabel Valli; Paolo Fusar-Poli; Cinzia Perlini; Fern Day; Stephen J Wood; Steven C Williams; Philip K McGuire Journal: Schizophr Bull Date: 2009-11-23 Impact factor: 9.306
Authors: Christine I Hooker; Emily E Carol; T J Eisenstein; Hong Yin; Sarah Hope Lincoln; Laura M Tully; David Dodell-Feder; Mor Nahum; Matcheri S Keshavan; Larry J Seidman Journal: Schizophr Res Date: 2014-06-18 Impact factor: 4.939
Authors: Nancy Haff; Mitesh S Patel; Raymond Lim; Jingsan Zhu; Andrea B Troxel; David A Asch; Kevin G Volpp Journal: Am J Health Promot Date: 2015 May-Jun
Authors: Patrick D McGorry; Barnaby Nelson; G Paul Amminger; Andreas Bechdolf; Shona M Francey; Gregor Berger; Anita Riecher-Rössler; Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Merete Nordentoft; Ian Hickie; Philip McGuire; Michael Berk; Eric Y H Chen; Matcheri S Keshavan; Alison R Yung Journal: J Clin Psychiatry Date: 2009-06-30 Impact factor: 4.384
Authors: Danielle A Schlosser; Melissa Fisher; David Gard; Daniel Fulford; Rachel L Loewy; Sophia Vinogradov Journal: Schizophr Res Date: 2014-07-05 Impact factor: 4.939
Authors: Henry W Mahncke; Sarah-Jane Kim; Annika Rose; Catherine Stasio; Peter Buckley; Stanley Caroff; Erica Duncan; Sarah Yasmin; L Fredrik Jarskog; J Steven Lamberti; Keith Nuechterlein; Martin Strassnig; Dawn Velligan; Joseph Ventura; Trina Walker; T Scott Stroup; Richard S E Keefe Journal: Schizophr Res Date: 2019-03-28 Impact factor: 4.939
Authors: William C Hochberger; Yash B Joshi; Michael L Thomas; Wendy Zhang; Andrew W Bismark; Emily B H Treichler; Melissa Tarasenko; John Nungaray; Joyce Sprock; Lauren Cardoso; Neal Swerdlow; Gregory A Light Journal: Neuropsychopharmacology Date: 2018-10-30 Impact factor: 7.853
Authors: Corby L Dale; Ethan G Brown; Alexander B Herman; Leighton B N Hinkley; Karuna Subramaniam; Melissa Fisher; Sophia Vinogradov; Srikantan S Nagarajan Journal: Schizophr Res Date: 2019-10-21 Impact factor: 4.939
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Ricardo E Carrión; Barbara A Cornblatt; Cynthia Z Burton; Ivy F Tso; Andrea M Auther; Steven Adelsheim; Roderick Calkins; Cameron S Carter; Tara Niendam; Tamara G Sale; Stephan F Taylor; William R McFarlane Journal: Am J Psychiatry Date: 2016-07-01 Impact factor: 18.112